Hematology Pipeline Update (February 2015, Volume 1, Issue 2.1)

Hematology Pipeline Update

Volume 1, Issue 2.1

A special edition featuring drug updates from the 2014 ASH Annual Meeting.

Table of Contents

Hematology Pipeline Update

Fusion Protein Therapies for Hemophilia A and B

Sunday, February 1st, 2015
Patients with hemophilia A and B may benefit from the less-frequent dosing regimens of two recently FDA-approved fusion protein therapies: recombinant coagulation factor VIII...

Optimizing Treatment of Bleeding Episodes in Acquired Hemophilia A

Sunday, February 1st, 2015
Two studies reported at the 2014 ASH Annual Meeting described how to best optimize OBI-1 (antihemophilic factor , porcine sequence), which was recently approved...

AG-221 Clinical Results Promise “Revolutionary” Approach in AML

Sunday, February 1st, 2015
Early clinical findings with AG-221 – a first-in-class potent, selective oral inhibitor of mutated isocitrate dehydrogenase 2 (IDH2) – reveal durable responses, including complete...

Promising Results for Elotuzumab Push Monoclonal Antibody Into Phase 3 Trial

Sunday, February 1st, 2015
Adding the new agent elotuzumab to traditional regimens of lenalidomide and low-dose dexamethasone has been found to produce high response rates in patients with...

Boosting Healthy Red Blood Cell Production to Target Anemia in MDS and Beta-Thalassemia

Sunday, February 1st, 2015
A new class of agents developed to enhance the production of healthy red blood cells (RBCs) provides a much-needed alternative to current treatment options...

New Treatment Option for Relapsed or Refractory Multiple Myeloma

Sunday, February 1st, 2015
Findings from a large clinical trial could pave the way for a new standard therapeutic approach to patients with refractory or relapsed and refractory...

New Drug Class Could Fill Unmet Need in Treatment of Multiple Myeloma

Sunday, February 1st, 2015
A new class of drugs designed to attack malignant plasma cells could offer patients with multiple myeloma new treatment options, according to early clinical...

Brentuximab Vedotin Delivers Clinical Results in Both Pre- and Post-Transplant Hodgkin Lymphoma

Sunday, February 1st, 2015
Brentuximab vedotin, an antibody-drug conjugate that targets CD30-positive cells, was the focus of much attention at the 56th ASH Annual Meeting. Two studies highlighted...

Update on Idelalisib + Rituximab in Relapsed and Elderly CLL Patients

Sunday, February 1st, 2015
The combination of idelalisib with rituximab prolonged progression-free survival (PFS) for patients with relapsed chronic lymphocytic leukemia (CLL), according to an oral presentation at...

Ibrutinib + Rituximab Benefits Patients With Pre-Treated Lymphoma and Leukemia

Sunday, February 1st, 2015
The combination of ibrutinib and rituximab is a promising treatment option for patients with relapsed or refractory blood cancers, according to results of two...

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

Sunday, February 1st, 2015
A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

Sunday, February 1st, 2015
For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

SHARE